Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Current and Novel Alkylators in Multiple Myeloma

Version 1 : Received: 3 March 2021 / Approved: 4 March 2021 / Online: 4 March 2021 (10:02:33 CET)

A peer-reviewed article of this Preprint also exists.

Schjesvold, F.; Oriol, A. Current and Novel Alkylators in Multiple Myeloma. Cancers 2021, 13, 2465. Schjesvold, F.; Oriol, A. Current and Novel Alkylators in Multiple Myeloma. Cancers 2021, 13, 2465.

Journal reference: Cancers 2021, 13, 2465
DOI: 10.3390/cancers13102465

Abstract

A large number of novel treatments for myeloma have been developed and approved, however alkylating drugs continue to be part of standard regimens, additionally, novel alkylators are currently being developed. We performed a non-systematized literary search for relevant papers and communications at large conferences, as well as exploiting the authors knowledge of the field to review the history, current use and novel concepts around traditional alkylators cyclophosphamide, bendamustine and melphalan and current data on the newly developed pro-drug melflufen. Even in the era of targeted treatment and personalized medicine, alkylating drugs continue to be part of standard-of-care in myeloma, and new alkylators are coming to the market.

Keywords

alkylator; myeloma; melflufen; melphalan; bendamustine; cyclophosphamide

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.